STACKER2 EUROPE - STACKER 4 POWDER Fruit Punch
Food supplement declared in France, decision dated 15 July 2026
STACKER2 EUROPE - STACKER 4 POWDER Fruit Punch (STACKER2 EUROPE) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- STACKER2 EUROPE
- Food business operator placing the product on the market
- Stacker2 Europe B.V.
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Poudre
- Daily dose
- 1,5 g (1 cuillère doseuse) par jour
- Intended populations
- Hommes et femmes de 18 ans et plus
- Not recommended for (according to the manufacturer)
- Adolescents (moins de 18 ans), Femmes allaitantes, Femmes enceintes, Insuffisance rénale, Problèmes cardiaques, Sous traitement antihypertenseur, Sous traitement pour la thyroïde, Ulcère (estomac ou duodenum)
- Flavourings
- Fruit Punch
Declaration 370924, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Camellia sinensis (L.) Kuntze | Feuille | Extrait sec hydroalcoolique | 50 mg |
| Ilex paraguariensis A. St.-Hil. | Feuille | Extrait sec aqueux | 35 mg |
| Paullinia cupana Kunth | Graine | Extrait sec hydroalcoolique | 25 mg |
| Capsicum annuum L. | Fruit | Extrait sec hydroalcoolique | 10 mg |
| Cola acuminata (P.Beauv.) Schott et Endl. | Graine | Extrait sec aqueux | 4 mg |
| Eleutherococcus senticosus (Rupr. et Maxim.) Maxim | Racine | Extrait sec hydroalcoolique | 2 mg |
Substances
| Name | Per day |
|---|---|
| caféine | 160 mg |
Additives
E955, E160a, E330
Other ingredients
poudre de betterave
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Ne pas laisser à la portée des jeunes enfants. Ne pas consommer une quantité journalière de 800 mg ou plus d'épigallocatéchine-3-gallate (EGCG). Ne doit pas être consommé si vous prenez le même jour d'autres produits contenant du thé vert. Ne doit pas être consommé par les femmes enceintes ou allaitantes et par les enfants de moins de 18 ans. Ne doit pas étre consommé à jeun. Déconseillé en cas de troubles ou d'insuffisance cardiaque ou rénale œdémateuses, d'ulcère gastro-duodénal, d'hypertension artérielle, ou d'hyperthyroidie. En cas de traitements médicamenteux, demander conseil à un professionnel de santé.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Capsicum annuum L.
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
Read the warning, when it applies and the studies cited
ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS
Route of administration: Oral (ESCOP 2003; Bradley 1992)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- caféine
Read the warning, when it applies and the studies cited
CAFFEINE
Route of administration: Oral (Higdon and Frei 2006)
Cautions and warnings
Applies to products providing 100 mg to 400 mg caffeine, per day1.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).
7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.
Applies to products providing more than 300 mg caffeine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing 400 mg or more caffeine, per day.
When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Applies to products providing more than 400 mg caffeine per day.
Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).
7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing 200 mg or more caffeine, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing more than 400 mg caffeine, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: All products except those making a diuretic claim1.
When using this product diuretic effect may occur.
1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : STACKER2 EUROPE
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.